• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.11% Nasdaq Up0.41%

    More On WL6.DE

    Quotes

    Charts

    News & Info

    Company

    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates

    Ownership

    • Major Holders
    • Insider Transactions
    • Insider Roster

    Financials


    Wilex AG (WL6.DE)

    -XETRA
    1.81 Up 0.06(3.31%) Jul 1, 6:24AM EDT
    ProfileGet Profile for:
    Wilex AG
    Grillparzerstrasse 18
    Munich, 81675
    Germany - Map
    Phone: 49 89 41 31 38 0
    Fax: 49 89 41 31 38 99
    Website: http://www.wilex.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:48

    Business Summary 

    WILEX AG operates as a biopharmaceutical company that focuses on oncology and antibodies. The company’s portfolio includes diagnostic and therapeutic product candidates for the detection and treatment of various types of cancer based on antibodies and small molecules. It develops RENCAREX, a Phase III product candidate for the treatment of clear cell renal cell carcinoma; REDECTANE, which has completed a Phase III trial for the treatment of kidney cancer; and MESUPRON that has completed Phase IIa clinical trials for the treatment of pancreatic and breast cancers. WILEX AG also provides preclinical contract services and an antibody drug conjugate technology platform. The company was formerly known as WILEX Biotechnology GmbH and changed its name to WILEX AG in February 2001. WILEX AG was founded in 1997 and is headquartered in Munich, Germany.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Wilex AG

    Key Executives 
     PayExercised
    Dr. Jan Schmidt-Brand , 58
    Chief Financial Officer and Member of the Exec. Management Board
    300.00KN/A
    Dr. Paul Bevan Ph.D., 68
    Head of R&D and Member of the Exec. Board
    203.00KN/A
    Prof. Andreas Pahl ,
    Chief Scientific Officer, Head of R&D and Member of the Exec. Management Board
    N/AN/A
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.